Join
Live feed
·
PRReleasevia Quantisnow
Stoke Therapeutics Inc. logo

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
STOK· Stoke Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.) and more on Quantisnow.